Lucid Diagnostics Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LUCD$0.40-4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(45,529) | $(52,666) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization expense | 1,167 | 2,499 |
| Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan | 4,183 | 5,762 |
| Stock-based compensation - PAVmed Inc. 2014 Equity Plan | 351 | 1,060 |
| Change in fair value - Senior Secured Convertible Note | (5,394) | 2,980 |
| Loss on issue - Senior Secured Convertible Note | — | 1,111 |
| Debt extinguishment loss - Senior Secured Convertible Note | 5,167 | 26 |
| APA-RDx: Issue common stock - termination payment | — | 713 |
| Amortization of common stock payment for vendor service agreement | 346 | 23 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | (28) |
| Prepaid expenses and other current assets | 1,159 | (1,160) |
| Accounts payable | 96 | 89 |
| Accrued expenses and other current liabilities | (1,012) | 2,394 |
| Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee | (4,674) | 4,380 |
| Net cash flows used in operating activities | (44,140) | (32,817) |
| Cash flows from investing activities | ||
| Purchase of equipment | (296) | (221) |
| Purchase of intellectual property from PAVmed Inc. | (350) | — |
| Net cash flows used in investing activities | (646) | (221) |
| Cash flows from financing activities | ||
| Proceeds – issue of preferred stock | 29,798 | 18,625 |
| Proceeds – issue of Senior Secured Convertible Notes | 21,615 | 10,000 |
| Payment – repayment of Senior Secured Convertible Note | (3,616) | — |
| Proceeds – issue of common stock – At-The-Market Facility | — | 284 |
| Proceeds – exercise of stock options | 4 | — |
| Proceeds – issue common stock – Employee Stock Purchase Plan | 447 | 551 |
| Net cash flows provided by financing activities | 48,248 | 29,460 |
| Net increase (decrease) in cash | 3,462 | (3,578) |
| Cash, beginning of period | 18,896 | 22,474 |
| Cash, end of period | $22,358 | $18,896 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.